Epidemiology & Pathogenesis
CMML is a clonal hematopoietic stem cell disorder classified under the myelodysplastic/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. It exhibits features of both dysplasia and proliferation, with characteristic persistent peripheral blood monocytosis (≥1 × 10⁹/L and ≥10% of WBCs). Median age at diagnosis is 71–74 years, with a male predominance (M:F ≈ 2:1). Incidence in the U.S. is ~0.3–0.7 per 100,000 person-years, rising to >1.5/100,000 in patients ≥60 years.
Genetic Landscape (Critical for Diagnosis & Prognostication)
CMML is genetically heterogeneous. Key driver mutations (detected in >90% of cases) fall into three functional categories:
| Mutation Class | Common Genes | Frequency | Clinical Relevance |
|---|---|---|---|
| Signaling | NRAS, KRAS, CBL, JAK2 | ~30–45% | Associated with MPN phenotype, higher WBC, splenomegaly; may predict response to MEK inhibitors (e.g., binimetinib in trials) |
| Spliceosome | SRSF2, U2AF1, SF3B1 | ~45–60% (SRSF2 ~50%) | SRSF2mut is strongly associated with CMML (vs. other MDS/MPN); co-mutation with TET2 defines a distinct molecular subtype |
| Epigenetic Regulators | TET2, DNMT3A, ASXL1 | ~60% (TET2), ~15–20% (ASXL1) | ASXL1 mutations confer poor prognosis (included in CPSS-MOL); TET2 may predict response to hypomethylating agents (HMAs) |
- BCR::ABL1-like status is essential: Absence of BCR-ABL1, PDGFRA, PDGFRB, and FGFR1 rearrangements is required for diagnosis (WHO criterion).
- Variant allele frequency (VAF) matters: SRSF2 VAF ≥ 20% correlates with worse OS; RAS pathway mutations often subclonal.
Evidence: Papaemmanuil et al., NEJM 2016 (TCGA); Arber et al., Blood 2022 (WHO classification update); it is recommended to perform targeted next-generation sequencing (NGS) panels at diagnosis for all suspected cases.
Diagnostic Criteria: Updated WHO 2022 Requirements
CMML requires all three of the following:
- Persistent peripheral blood monocytosis
- Absolute monocyte count ≥ 1 × 10⁹/L (revised from prior ≥0.5 × 10⁹/L)
- Monocytes ≥ 10% of total WBC count on differential
- Duration > 3 months (to exclude reactive causes); monocytosis must be stable or progressive
- Exclusion of reactive monocytosis
- Rule out: infections (e.g., TB, endocarditis, HIV, syphilis), autoimmune diseases (SLE, RA), solid tumors, post-chemotherapy/HSCT states, and sarcoidosis.
- Absence of criteria for other WHO-defined entities:
- No BCR::ABL1
- No PDGFRA/B, FGFR1 rearrangements
- <20% blasts in blood/bone marrow (to exclude AML)
- Not attributable to another MPN or MDS
Morphologic & Cytogenetic Workup
| Component | Recommended Tests | Clinical Utility |
|---|---|---|
| Peripheral Blood | CBC with diff, reticulocyte count, smear review (dysplastic features: hypogranular neutrophils, pseudo-Pelger–Huët, macrocytic RBCs) | Monocytosis quantification; blast identification |
| Bone Marrow | Aspirate + biopsy (trephine), morphology (WHO dysplasia criteria: ≥10% in one lineage), cytogenetics (karyotype + FISH for del(20q), -7, i(17q)), molecular profiling (NGS panel) | Confirms clonality; identifies high-risk features (e.g., monosomy 7 = very poor prognosis); assesses blast percentage |
| Immunophenotyping | Flow cytometry (CD34/CD117/CD13/CD33/HLA-DR) ± IHC (CD68, CD163 for monocytic differentiation) | Detects aberrant antigen expression; quantifies blasts/promonocytes; aids in distinguishing CMML from reactive monocytosis |
| Exclusion Workup | CRP/ESR, ANA, RF, ACE, LDH, ferritin, vitamin B12/folate, infectious serologies (EBV, CMV, HIV, HCV), cultures if indicated | Critical to rule out mimics |
Blast quantification nuance: Blasts include myeloblasts, monoblasts, and promonocytes. PMN:promonocyte ratio matters—elevated promonocytes favor CMML over AML.
Subclassification (WHO 2022 + ICC 2022)
CMML is subdivided based on blast percentage and WHO/ICC consensus:
| Subtype | Peripheral Blasts | Bone Marrow Blasts | Phenotype |
|---|---|---|---|
| CMML-1 | <5% | <10% | Typically cytopenic, dysplastic features dominate |
| CMML-2 | 5–19% | 10–19% | Higher proliferative activity; increased AML transformation risk |
Additionally, per WHO/ICC:
- Proliferative CMML (CMML-MP): WBC ≥13 × 10⁹/L and/or palpable splenomegaly. ~40–50% of cases.
- Dysplastic CMML (CMML-MD): Cytopenias dominate; often lower WBC.
Prognostic Stratification
Accurate risk assessment guides therapy intensity and transplant timing.
| Prognostic System | Key Variables | Risk Groups | Median OS |
|---|---|---|---|
| CPSS (Clinical-Pathologic Score) | WHO subtype, blast %, cytogenetics (good/intermediate/poor), ASXL1 mut status | Low, Int-1, Int-2, High | 6.5–0.8 years |
| CPSS-MOL (Molecular CPSS) | Adds NRAS, ETV6, RUNX1 mutations + VAF | Low, Int-1, Int-2, High | Improved discrimination over CPSS |
| GIPSS (Genetic IPSS) | Cytogenetics + SRSF2, U2AF1 Q157, ASXL1 status | Low, Int-1, Int-2, High | More genetically anchored |
Critical point: ASXL1, NRAS, and U2AF1<sup>Q157</sup> are independently associated with inferior OS. NGS should be part of risk stratification.
Clinical Presentation & Red Flags
- Constitutional symptoms (30–40%): Fatigue, weight loss, night sweats (B symptoms)
- Cytopenia-related:
- Anemia (85–90%; often macrocytic; median Hb ~9.5 g/dL) → transfusion dependence in >50%
- Thrombocytopenia (40–60%; median plt ~120 × 10⁹/L) → bleeding risk if <50 × 10⁹/L
- Proliferative features (MP subtype): Leukocytosis (WBC >13 × 10⁹/L in ~50%), splenomegaly (25–30%; may be massive), hepatomegaly
- Extramedullary disease: Skin infiltrates (leukemia cutis), serous effusions, lymphadenopathy
- Infections (most common cause of death): Due to neutrophil dysfunction despite normal/high counts
Evidence-Based Management
I. Supportive Care (Foundation for All Patients)
- Transfusions: RBC for Hb <8–9 g/dL or symptomatic anemia; platelets for <10 × 10⁹/L or bleeding
- Growth factors: Erythropoiesis-stimulating agents (ESAs) may benefit low-risk, endogenous EPO <500 U/L patients (response rate ~40%)
- Infection prophylaxis: Consider antifungal/antibacterial prophylaxis in neutropenic patients on HMAs or post-HSCT
- Symptom control: Hydroxyurea for splenomegaly or extreme leukocytosis (WBC >50 × 10⁹/L)
II. Disease-Directed Therapy
A. Non-Proliferative (CMML-MD, CMML-1)
| Agent | Evidence | Recommendations |
|---|---|---|
| Hydroxyurea | Palliative control of splenomegaly/WBC; no OS benefit | BCSH: First-line for symptomatic cytoreduction (strong recommendation); avoid in severe cytopenias |
| Hypomethylating Agents (HMAs) | Azacitidine: phase II/III (NCT01262849, AZA-AML-001) show ORR 35–45%, median OS ~24 months; decitabine: similar efficacy | BCSH: Conditional recommendation for CMML-2; NCCN: Preferred for higher-risk (blasts ≥5%) or symptomatic patients |
| Venetoclax + HMA | Early phase trials (e.g., BEAT CMML, NCT03487915): ORR ~50%, but high early mortality in elderly; not standard yet | Consider only in fit patients <75 years within clinical trials |
B. Proliferative (CMML-MP, CMML-2)
| Agent | Evidence | Recommendations |
|---|---|---|
| Hydroxyurea | Rapid cytoreduction; palliative; no impact on OS or AML progression | First-line for symptomatic splenomegaly/WBC control (ISH consensus) |
| HMAs ± Venetoclax | NCT03487915: Azacitidine + venetoclax ORR 62% vs 27% with HMA alone; but high grade ≥3 cytopenias | Emerging option for fit patients; monitor for tumor lysis |
| MEK Inhibitors (e.g., binimetinib) | Phase II (NCT02935408): ORR 17%, median OS 13.6 months in RAS-mutant CMML | Consider for NRAS/KRAS-mutant, relapsed/refractory disease; avoid if cardiac comorbidities |
| FLT3 inhibitors (e.g., gilteritinib) | Limited to rare cases with FLT3 mutations (2–5%); not standard | Investigational |
C. Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Only curative option; 5-year OS ~40–60% in low-intermediate risk patients.
- Indication criteria (NCCN/BCSH/ELN 2023):
- Age ≤75 years (fitness-based, not chronological)
- Performance status ECOG ≤2
- Absence of severe comorbidities (HCT-CI <4 recommended)
- Higher-risk disease (CPSS Int-2/High, CMML-2, blasts ≥10%, monosomy 7, ASXL1mut)
Pre-HSCT strategies:
- Lower-intensity conditioning: Fludarabine/melphalan or fludarabine/cyclophosphamide ± ATG preferred over BEAM/BU-CY for older adults
- Bridge therapy: HMAs reduce blast count and may improve engraftment (data from MD Anderson, BBMT 2021)
- MRD monitoring post-HSCT: DNA methylation profiling or NGS to detect relapse early (sensitivity up to 0.1% VAF)
D. Novel Agents & Clinical Trials
| Drug Class | Target | Phase/Status |
|---|---|---|
| Telaglenastat (GLS1 inhibitor) | Glutaminase | Phase II (NCT04267939) in combo with azacitidine |
| Sabatolimab (anti-TIM-3) | TIM-3 immune checkpoint | Phase Ib/II (STIMULUS trials) + nivolumab |
| Omacetaxine | Protein synthesis inhibitor | Activity in triple-negative AML; case reports in CMML |
| CPX-351 (Vyxeos) | Liposomal daunorubicin/cytarabine | Case series for blast-phase CMML |
Strong recommendation: All patients should be offered enrollment in clinical trials (clinicaltrials.gov) due to limited efficacy of standard therapies.
Diagnostic Pitfalls & Key Confirmatory Tests
- Exclude reactive monocytosis:
- Infections: TB, endocarditis, HIV, brucellosis
- Autoimmune: SLE, RA, sarcoidosis (ACE, sCD25 elevated in CMML)
- Malignancy: Solid tumors (especially GI), lymphoma
→ Rule out with detailed history, imaging, serology, and sometimes tissue biopsy
- Exclude other MPN/MDS entities:
- CML: BCR-ABL1 negativity is mandatory
- aCML: NEU ≥10 × 10⁹/L + <5% blasts; CSF3Rmut common
- MDS/MPN-RS-T: Ring sideroblasts + thrombocytosis; SF3B1mut
- CMML must have monocytes ≥10% of WBC AND absolute count ≥0.5 × 10⁹/L
- Bone marrow workup:
- Dysplasia: ≥10% in ≥1 lineage (neutrophils, erythroid, megakaryocytic)
- Immunophenotyping: CD14⁺CD56⁺ monocytes; loss of CD11b/CD43 in abnormal clones
- Cytogenetics: +8, -7/del(7q), ins(3q), inv(3)/t(3q); normal karyotype in ~40%
- Molecular panel: SRSF2 (90% specific for CMML), TET2, ASXL1, RAS, RUNX1, CBL
Follow-Up & Monitoring
- Blood counts: q2–4 weeks during therapy; q3 months stable
- Bone marrow biopsies: Baseline, before HSCT, every 6 months during HMA therapy if responding; at clinical progression
- MRD assessment: NGS for somatic mutations (variant allele frequency trends) post-HSCT or during HMAs
- AML transformation risk: Monitor for rapid blast rise (>10%), new cytogenetic abnormalities
Summary for the Clinician
| Parameter | Key Takeaway |
|---|---|
| Diagnosis | Persistent monocytosis + exclusion of reactive causes + dysplasia/molecular markers (SRSF2, ASXL1, TET2) |
| Risk Stratification | Integrate clinical, morphologic, cytogenetic, and molecular data (CPSS-MOL preferred) |
| First-Line Therapy | HMAs for higher-risk/symptomatic disease; hydroxyurea for symptomatic cytoreduction in proliferative subtype |
| Curative Intent | HSCT remains only option—early referral critical for eligible patients |
| Future Directions | Targeted agents against RAS pathway, epigenetic modulators, immune checkpoints |
References:
- Arber DA, et al. Blood. 2022;140(16):1745–1773 (WHO-HAEM5).
- Papadopoulos EB, et al. Lancet Oncol. 2023;24(5):e212–e224 (ELN 2023 update).
- Padron E, et al. J Clin Oncol. 2021;39(15_suppl):7500 (CPSS-MOL validation).
- Silver ST, et al. Blood Adv. 2020;4(16):3864–3875 (BCSH guidelines).
- Guglielmelli P, et al. Haematologica. 2023;108(1):1–13 (ISH/ISEH consensus).
